Replies to post #135473 on Biotech Values

[Superfly15]

Beware of biotech companies who issue folksy letters to shareholders from the CEO; CVM is a case in point:

I enjoyed these yummy tidbits the most ::

As you may know, I am not allowed to discuss the study results at this early stage. However, that being said, our confidence may be best expressed by the decision made to expand the trial into four extra territories at additional expense and effort

how much value will this create for our shareholders? No one knows exactly, but it should be significant.

The man doesn't know how much his company would be worth?